



# Educational Meeting on Immunology and Cellular Therapy in Plasma Cell Disorders

Hamburg, Germany  
24 - 26 November 2023

## WELCOME

Moin!

On behalf of the Scientific Committee, we are pleased to invite you to the 1st Joint Educational Meeting of the Chronic Malignancies Working Party (CMWP) and the Cellular Therapy and Immunobiology Working Party (CTIWP) of the EBMT, to be held in Hamburg, Germany, on 24th to 26th November 2023. This event will present the most recent advances and new perspectives in the field of immunology and cellular therapy for multiple myeloma and plasma disorders, including current practical challenges and new patient-centered perspectives.

The plenary conference programme is designed to place emphasis on leading-edge basic and clinical research. This shall be a platform for deliberate interaction, sharing of experiences and active and open scientific discourse and debate. Everything will be embedded in the Beauty of Germany's north, Hamburg, with a dedicated and warm environment for active networking.

Annalisa Ruggeri, CTIWP Chair  
Donal McLornan, CMWP Chair  
Nico Gagelmann, local organiser

**Friday, 24 November 2023**

*Plenary Room*

<b>10:00 - 13:00</b>	<b>Chronic Malignancies Working Party Scientific Business Meeting</b> Open for everybody
<b>13:00 - 14:00</b>	<b>Lunch Break</b>
<b>14:00 - 16:00</b>	<b>Chronic Malignancies Working Party Scientific Business Meeting</b> Open for everybody
<b>16:00 - 16:15</b>	<b>Coffee Break</b>
<b>16:15 - 17:15</b>	<b>Joint Meeting</b>
<b>17:15 - 18:00</b>	<b>Keynote Lecture</b> Placement of cellular therapies in treatment algorithm of PCDs    Carlos Fernández de Larrea (ES)

*Breakout Room*

<b>10:00 - 13:00</b>	<b>Cellular Therapy and Immunobiology Working Party Scientific Business Meeting</b> Open for everybody
<b>13:00 - 14:00</b>	<b>Lunch Break</b>
<b>14:00 - 16:00</b>	<b>Cellular Therapy and Immunobiology Working Party Scientific Business Meeting</b> Open for everybody
<b>16:00 - 16:15</b>	<b>Coffee Break</b>
<b>16:15 - 17:15</b>	<b>Joint Meeting at Plenary Room</b>

## Saturday, 25 November 2023

### Plenary Room

#### 09:00 – 10:00

#### Session I: Basics of myeloma

*Chair: Meral Beksac (TR)*

09:00-09:15

Diagnostic and treatment algorithm in MM

Patrick Hayden (IE)

09:15-09:30

Diagnostic and treatment algorithm in amyloidosis

Monique Minnema (NL)

09:30-09:45

Diagnostic and treatment algorithm in WM, MGCS, MGRS

Shirley D'Sa (UK)

09:45-10:00

Q&A

#### 10:00 – 11:00

#### Session II: Preclinical models in MM

*Chair: Florent Malard (FR)*

10:00-10:15

Genomic evolution

Niels Weinhold (DE)

10:15-10:30

Omics

Marc Raab (DE)

10:30-10:45

Microbiome

Florent Malard (FR)

10:45-11:00

Q&A

#### 11:00 – 11:30

#### Coffee Break

#### 11:30 – 12:35

#### Session III: Immune microenvironment in disease

*Chairs: Joanna Drozd-Sokolowska (PL) – Kavita Raj (UK)*

11:30-11:45

T-cells

Kim de Veirman (NL)

11:45-12:00

NK cells

Michael O'Dwyer (IE)

12:00-12:15

Mechanisms of EMD

Tomáš Jelinek (CZ)

12:15-12:20

Case presentation: Refractory Multiple Myeloma with Challenging Extramedullary Disease

Esra Gülderen (TR)

12:20-12:35

Q&A

#### 12:35 - 13:30

#### Session IV: Novel cellular therapies

*Chair: Lydia Lee (UK)*

12:35-12:45

Novel targets

Luis G. Rodríguez-Lobato (ES)

12:45-12:55

NK cells, macrophages, fibroblasts

Niels Weinhold (DE)

12:55-13:05

Harvesting the therapeutic potential of gdT cells for cancer immune therapies

Jürgen Kuball (NL)

13:05-13:15

Immune signalling at the tumour: bone marrow niche in multiple myeloma: a view to a kill

Graeme Sullivan (IE)

13:15-13:30

Q&A

#### 13:30 - 14:30

#### Lunch Break

**14:30 – 15:15**

**Session V: Procedural aspects**

*Chair: Stefan Schönland (DE)*

14:30-14:45

Cell collection and manufacturing

Christian Chabannon (FR)

14:45-15:00

AI

Alexander Oeser (DE)

15:00-15:15

Q&A

**15:15 – 16:00**

**Session VI: New and "old" kids on the block**

*Chair: Gösta Gahrton (SE)*

15:15-15:30

Finding the optimal drug combination for rrMM

Fredrik Schjesvold (NO)

15:30-15:45

Role of autograft

Mauricette Michallet (FR)

15:45-16:00

Q&A

**16:00 – 16:30**

**Coffee Break**

**16:30 – 17:30**

**Session VII: Current state of CAR-T in PCD**

*Chair: Nico Gagelmann (DE)*

16:30-16:45

Ide-cel and cilta-cel: trial insights

Yael Cohen (IL)

16:45-17:00

Real-world and GOCART

Nico Gagelmann (DE)

17:00-17:15

Academic

Lydia Lee (UK)

17:15-17:30

Q&A

**17:30 – 18:15**

**Keynote lecture**

*Chair: Anna Sureda (ES)*

Lessons and new insights in allogeneic CAR-T and transplant

Nicolaus Kröger (DE)

**Saturday, 25 November 2023**

*Breakout Room  
Nurses' track*

<b>09:10 – 09:15</b>	<b>Welcome</b>	
<b>09:15 – 10:15</b>	<b>Session I: Multiple myeloma, the basics, and new treatment options</b>	
09:15–10:15	Multiple myeloma (the basics), new treatment options, and what's important in the patients screening for CART cell therapy in the MM field (frail/unfit screening)	Laurent Garderet (FR)
<b>10:15 – 11:00</b>	<b>Session II (part I): Toxicity during CART cell therapy and bispecific</b>	
10:15–11:00	CAR-T	Maaïke de Ruijter (NL)
<b>11:00 – 11:30</b>	<b>Coffee Break</b>	
<b>11:30 – 12:15</b>	<b>Session II (part II): Toxicity during CART cell therapy and bispecific</b>	
11:30–12:15	Bispecifics	Marianne Elshoud (NL)
<b>12:15 – 13:15</b>	<b>Session III: The role of the research nurse and nurse specialist in the patient Pathway (CART and bispecific)</b>	
12:15–12:45	CAR-T	Sandy Kruyswijk (NL)
12:45–13:15	Bispecifics	Maaïke de Ruijter (NL)
<b>13:15 – 13:30</b>	<b>Closing Remarks</b>	
<b>13:30 – 14:30</b>	<b>Lunch Break</b>	

**Sunday, 26 November 2023**

*Plenary Room*

**09:00- 10:00**

**Session VIII: Biology of response and relapse**

*Chair: Annalisa Ruggeri (IT)*

09:00-09:15  
09:15-09:30  
09:30-09:45  
09:45-10:00

High-risk Myeloma transplant vs CART  
Antigen loss and microenvironment  
Immune monitoring  
Q&A

Christoph Schaefers (DE)  
Sarah Gooding (UK)  
Christof Scheid (DE)

**10:00 - 10:55**

**Industry Symposium on “Novel therapies in multiple myeloma”**

*Kindly sponsored by Janssen*

*Chair: Hermann Einsele (DE)*

10:00-10:10  
10:10-10:25  
10:25-10:40  
10:40-10:55

Novel immune and cellular therapies  
CAR T cells - patient selection and treatment of toxicities  
Management of infections & mitigations strategies  
Q&A

Hermann Einsele (DE)  
Christof Scheid (DE)  
Cyrus Khandanpour (DE)

**10:55 – 11:25**

**Coffee Break**

**11:25 – 12:25**

**Session IX: Monitoring and treating resistance**

*Chair: Yael Cohen (IL)*

11:25-11:40  
11:40-11:55  
11:55-12:10  
12:10-12:25

Multi-targeting  
Role of MRD  
Bispecifics  
Q&A

Mohamad Mohty (FR)  
Noemi Puig (ES)  
Hermann Einsele (DE)

**12:25 – 13:25**

**Session X: Patient fitness and toxicities**

*Chair: Donal McLornan (UK)*

12:25-12:40  
12:40-12:55  
12:55-13:10  
13:10-13:25

Is there "eligibility" for CAR-T?  
Mechanisms and strategies for neurotoxicity  
Hematotoxicity and others  
Q&A

Laurent Garderet (FR)  
Ibrahim Yakoub-Agha (FR)  
Meral Beksac (TR)

**13:25 – 13:40**

**Closing Remarks**

Donal McLornan (UK)  
Annalisa Ruggeri (IT)

## THANKS TO OUR SPONSORS

### Industry Symposium Partner



### Gold Partner



### Silver Partners



### Bronze Partners

